Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph early_phase_1
1
33%
Ph phase_1
1
33%
Ph phase_3
1
33%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(2)

Detailed Status

Withdrawn2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (33.3%)
Phase 11 (33.3%)
Phase 31 (33.3%)

Trials by Status

recruiting133%
withdrawn267%

Recent Activity

1 active trials
Showing 3 of 3
recruitingearly_phase_1

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

NCT06735690
withdrawnphase_3

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

NCT05711628
withdrawnphase_1

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

NCT02378922

Clinical Trials (3)

Showing 3 of 3 trials
NCT06735690Early Phase 1

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

Recruiting
NCT05711628Phase 3

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Withdrawn
NCT02378922Phase 1

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
3